<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719327</url>
  </required_header>
  <id_info>
    <org_study_id>CLNA-001-15S</org_study_id>
    <secondary_id>CX001261</secondary_id>
    <nct_id>NCT02719327</nct_id>
  </id_info>
  <brief_title>Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid</brief_title>
  <acronym>BRAVE-EPA</acronym>
  <official_title>Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by&#xD;
      2050. Compared to the general population, Veterans have a greater risk of AD, likely in part&#xD;
      due to their increased incidence of traumatic brain injury, post-traumatic stress disorder,&#xD;
      depression, and other vascular-related health issues. Based on available data, 423,000 new&#xD;
      cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies&#xD;
      to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to&#xD;
      evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid&#xD;
      (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD&#xD;
      pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with&#xD;
      increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD&#xD;
      would be reduced by 50% in this population and could have a profound effect on Veteran&#xD;
      quality of life and healthcare costs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a proof-of-concept, randomized, placebo-controlled, double-blind,&#xD;
      parallel-group clinical trial assessing the efficacy of 18 months of icosapent ethyl (IPE)&#xD;
      therapy on magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), and cognitive&#xD;
      biomarkers for AD in 150 cognitively-healthy Veterans ages 50-75 years. The overarching goal&#xD;
      of this trial is to assess whether icosapent ethyl beneficially affects intermediate&#xD;
      physiological measures associated with onset of AD in order to evaluate whether larger,&#xD;
      multi-site, longer-duration Alzheimer's prevention trials are warranted to assess more&#xD;
      definitive clinical outcomes. The proposed study aims to: 1) investigate the effects of 18&#xD;
      months of IPE vs. placebo on regional cerebral blood flow as measured by arterial&#xD;
      spin-labeling MRI; 2) determine the impact of 18 months of IPE vs. placebo on CSF biomarkers&#xD;
      of AD pathology; and 3) evaluate the effects of 18 months of IPE vs. placebo on cognitive&#xD;
      performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Anticipated">September 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization of icosapent ethyl 4 g daily vs matching placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional cerebral blood flow using arterial spin-labeling MRI</measure>
    <time_frame>18 months</time_frame>
    <description>Brain blood flow in a statistical region of interest will be measured through arterial spin-labeling MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease</measure>
    <time_frame>18 months</time_frame>
    <description>CSF beta-amyloid, total tau, and phosphorylated tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive performance</measure>
    <time_frame>18 months</time_frame>
    <description>Preclinical Alzheimer's Cognitive Composite (PACC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>icosapent ethyl (IPE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icosapent ethyl (IPE)</intervention_name>
    <description>Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo</description>
    <arm_group_label>icosapent ethyl (IPE)</arm_group_label>
    <other_name>Vascepa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gel cap placebo</intervention_name>
    <description>Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  United States Veteran eligible for VA care&#xD;
&#xD;
          -  Age 50-75 years, inclusive&#xD;
&#xD;
          -  Cognitively healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia or mild cognitive impairment on screening evaluation&#xD;
&#xD;
          -  Current use of fish oil supplements (requires 3 month wash-out period)&#xD;
&#xD;
          -  Active liver disease with AST or ALT greater than twice the upper limit of normal&#xD;
&#xD;
          -  Elevated creatine kinase greater than twice the upper limit of normal&#xD;
&#xD;
          -  Prior adverse reaction to statins or fish oil&#xD;
&#xD;
          -  Pregnant, nursing, or pregnancy planned&#xD;
&#xD;
          -  Use of medications that interact with icosapent ethyl&#xD;
&#xD;
          -  Current use of anticoagulants&#xD;
&#xD;
          -  Known hypersensitivity to fish and/or shellfish&#xD;
&#xD;
          -  Current use of other investigational drug&#xD;
&#xD;
          -  History of significant atherosclerotic cardiovascular disease or diabetes mellitus&#xD;
&#xD;
          -  Low-density lipoprotein (LDL) cholesterol &gt; or =190 mg/dL or &lt;80 mg/dL&#xD;
&#xD;
          -  Triglycerides &gt; or = 500 mg/dL&#xD;
&#xD;
          -  Creatinine &gt;1.8 mg/dL&#xD;
&#xD;
          -  Previous lumbar surgery with contraindication to lumbar puncture&#xD;
&#xD;
          -  Claustrophobia requiring sedation for MRI&#xD;
&#xD;
          -  Pacemaker or other contraindication for MRI&#xD;
&#xD;
          -  Consumption of &gt;200 mg per day omega-3 fatty acids in diet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M. Carlsson, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>William S. Middleton Memorial Veterans Hospital, Madison, WI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William S. Middleton Memorial Veterans Hospital, Madison, WI</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>October 6, 2022</last_update_submitted>
  <last_update_submitted_qc>October 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>brain blood flow</keyword>
  <keyword>cognition</keyword>
  <keyword>icosapent ethyl</keyword>
  <keyword>Vascepa</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

